Gustafson Tanya Lynn, Biller Barbara
From Animal Cancer Care Center, Fort Lauderdale, Florida (T.L.G.); and Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado (B.B.).
J Am Anim Hosp Assoc. 2019 Sep/Oct;55(5):243-248. doi: 10.5326/JAAHA-MS-6905.
Transitional cell carcinoma (TCC) is a locally aggressive tumor in dogs with low-to-moderate responses to traditional chemotherapeutic agents. Toceranib (TOC) phosphate represents a novel agent for the treatment of canine TCC. Thirty-seven dogs were identified who had received TOC for bladder tumor treatment. The TOC was generally well tolerated, although 56% of dogs had progression of azotemia while receiving TOC. A partial response to TOC was observed in 6.7% of dogs, and 80% of dogs had stable disease for a median duration of 128.5 days. Median time to progression was 96 days, and median survival time after the start of TOC was 149 days. There were no significant variables influencing time to progression or survival time in this group of dogs. This retrospective study suggests that TOC may be useful for the treatment of TCC. However, careful monitoring of renal function is recommended in patients with bladder tumors receiving TOC.
移行细胞癌（TCC）是犬类的一种局部侵袭性肿瘤，对传统化疗药物的反应为低至中度。磷酸托西拉尼（TOC）是一种用于治疗犬TCC的新型药物。确定了37只接受TOC治疗膀胱肿瘤的犬。TOC一般耐受性良好，尽管56%的犬在接受TOC治疗时出现氮质血症进展。6.7%的犬对TOC有部分反应，80%的犬病情稳定，中位持续时间为128.5天。中位进展时间为96天，开始使用TOC后的中位生存时间为149天。在这组犬中，没有显著变量影响进展时间或生存时间。这项回顾性研究表明，TOC可能对TCC的治疗有用。然而，建议对接受TOC治疗的膀胱肿瘤患者仔细监测肾功能。
